Skip to main content
SpringerLink
Log in

Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions

  • Allergy, Histamine and Kinins
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Levocabastine, selected from a series of cyclohexylpiperidine derivatives protects rats from compound 48/80-induced anaphylactic shock for at least 16 h at the oral dose of 0.0015 mg/kg. At the same dose histamine skin reactions and at slightly higher doses passive cutaneous anaphylactic reactions are inhibited. Blockade of passive cutaneous anaphylactic reactions is obtained with levocabastine, despite absence of peripheral serotonin antagonism and any other known non-specific action that may facilitate inhibition of passive anaphylaxis. In dogs allergic reactions are inhibited at oral doses 40 times lower than ketotifen. In guinea-pigs orally and topically administered levocabastine are remarkably effective against allergic conjunctivitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. C. J. E. Niemegeers, F. Awouters, J. M. van Nueten, S. de Nollin and P. A. J. Janssen,Protection of rats from compound 48/80-induced lethality. A simple test for inhibitors of mast cell-mediated shock. Archs. int. Pharmacodyn. Thér.234, 164–176 (1978).

    Google Scholar 

  2. F. Janssens, M. A. C. Janssen, F. Awouters, C. J. E. Niemegeers and G. Vanden Bussche,Chemical development of astemizole-like compounds. Drug Dev. Res.8, 27–36 (1986).

    Article  Google Scholar 

  3. R. A. Stokbroeckx, M. Luyckx, J. Willems, M. Janssen, J. Bracke, R. Joosen and J. Van Wauwe,Levocabastine (R 50 547): the protype of a chemical series of compounds with specific H 1-antihistaminic activity. Drug. Dev. Res.8, 87–93 (1986).

    Article  Google Scholar 

  4. F. Awouters, J. Vermeire, F. Smeyers, P. Vermote, R. van Beek and C. J. E. Niemegeers,Oral antiallergic activity in Ascaris hypersensitive dogs: A study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547). Drug. Dev. Res.8, 95–102 (1986).

    Article  Google Scholar 

  5. J. E. Leysen and W. Gommeren,Drug receptor dissociation time, new tool for drug research: receptor binding affinity and drug-receptor dissociation profiles of serotonin-S 2,dopamine-D 2,histamine-H 1 antagonists, and opiates. Drug. Dev. Res.8, 119–131 (1986).

    Article  Google Scholar 

  6. J. P. van Wauwe,Animal pharmacology of levocabastine: a new type of H 1-antihistamine well suited for topical application. InRhinoconjunctivitis, new perspectives in topical treatment. pp. 27–34 (Eds. N. Mygind and R. M. Naclerio). Hogrefe and Huber Publ., Toronto 1989.

    Google Scholar 

  7. D. J. Finney,Probit analysis. Cambridge University Press (1962).

  8. F. Awouters, C. J. E. Niemegeers and P. A. J. Janssen,Interaction of astemizole and other drugs with PCA, histamine, serotonin and compound 48/80-induced skin reactions in the rat. A procedure to determine anti-allergic effectiveness. Drug. Dev. Res.5, 137–145 (1985).

    Article  Google Scholar 

  9. P. A. J. Janssen, C. J. E. Niemegeers, F. Awouters, K. H. L. Schellekens, A. A. H. P. Megens and T. F. Meert,Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S 2 and dopamine D 2-antagonistic properties. J. Pharmac. Exp. Ther.244, 685–693 (1988).

    Google Scholar 

  10. J. Monbaliu, M. Michiels, R. Woestenborghs, I. Geuens, R. Gasparini and J. Heykants,Pharmacokinetics of levocabastine (R 50 547) in the dog. Naunyn-Schmiedebergs Arch. Pharmacol.330 (Suppl.), R15 (1985).

    Google Scholar 

  11. F. Awouters, C. J. E. Niemegeers and P. A. J. Janssen,Inhibitors of mast cell-mediated shock in the rat: relationship to histamine and serotonin antagonism. Drug. Dev. Res.1, 107–114 (1981).

    Article  Google Scholar 

  12. B. Björksten and N.-I. Max Kjiellman,Double-blind studies with levocabastine, sodium cromoglycate, and placebo in the topical treatment of children with allergic conjunctivitis. InRhinoconjunctivitis, new perspectives in topical treatment. pp. 49–52 (Eds. N. Mygind and R. M. Naclerio). Hogrefe and Huber Publ., Toronto 1989.

    Google Scholar 

  13. K. Holmberg, U. Pipkorn, B. Bake and L.-O. Blychert,Effects of topical treatment with H 1 and H 2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis. Allergy44, 281–287 (1989).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Janssen Research Foundation, B-2340, Beerse, Belgium

    F. Awouters, C. J. E. Niemegeers, T. Jansen, A. A. H. P. Megens & P. A. J. Janssen

Authors
  1. F. Awouters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. J. E. Niemegeers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. H. P. Megens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. A. J. Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Awouters, F., Niemegeers, C.J.E., Jansen, T. et al. Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions. Agents and Actions 35, 12–18 (1992). https://doi.org/10.1007/BF01990945

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01990945

Keywords

Search

Navigation